Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2025

Description

EXECUTIVE SUMMARY

The first successful transplant using cord blood-derived hematopoietic stem cells was conducted in October 1988. Since then, significant advancements have been made in the field of umbilical cord blood research. To date, over 40,000 umbilical cord blood transplants (UCBTs) have been performed globally, treating a wide range of conditions including hematologic, metabolic, immunologic, neoplastic, and neurologic disorders.

Cord blood storage began as a commercial service in the early 1990s, but it was not until 2008 that cord tissue storage was introduced commercially. The first company to offer this service was Taiwan's HealthBanks Biotech Company Ltd., followed by HealthBaby and Cryolife in Hong Kong in 2009. In the U.S., Cord Blood Registry (CBR) started offering cord tissue storage in July 2010. Today, nearly all U.S. cord blood banks and approximately one-third of global banks offer cord tissue storage services.

For placental banking, LifebankUSA began offering placental blood storage in 2006 and placental tissue storage in 2011. Americord Registry followed in September 2017 as the second U.S. bank to offer placental tissue banking. Internationally, a number of cord blood banks also provide placental blood and tissue storage services. Some have expanded into storing other stem cell types, such as dental pulp stem cells, with DentCell, a dental pulp stem cell bank, being controlled by Cryoholdco, the largest cord blood banking consolidator in Latin America. Additionally, a few banks have started storing adipose-derived stem cells.

The cord blood industry has experienced unprecedented levels of mergers and acquisitions (M&A) in recent years, leading to significant market consolidation, particularly in Europe, Latin America, and the U.S. The market is now predominantly controlled by a handful of large cord blood banking operators. This consolidation is notable given the rapid growth of the industry in the early 2000s. Significant consolidation has occurred in the U.S., Europe, Asia, and Latin America:

PBKM FamiCord has acquired most of the European market, including merging with it largest competitor Vita34 and acquiring assets following Cryo-Save AG's 2019 bankruptcy.
CooperSurgical has consolidated reproductive, newborn stem cell, and genetic services within the U.S., managing at least 1.1 million units.
Cryoholdco has amassed stem cell banking assets across Latin America, including four in Mexico, two in Colombia, two in Brazil, and one in Peru, totaling an estimated 300,000 units.
Sanpower Group dominates the Asian market through its ownership of Global Cord Blood Corporation and other assets across Southeast Asia, controlling over 1.2 million units.
India, with its burgeoning population of 1.4 billion, rivals China in size, making up approximately 36% of the world's 7.8 billion people. LifeCell International is the leading stem cell bank in India, storing over 320,000 units.

This consolidation has spurred many cord blood banks to explore new stem cell storage options and expand their services to include fertility and reproductive services, genetic testing, and cell therapy applications. The therapeutic potential of cord blood, cord tissue, placental blood, and amniotic fluid has driven the proliferation of storage services for these biomaterials.

Many cord blood banks have now expanded their offerings to include:

Reproductive and assisted fertility services
Pre- and post-natal genetic testing
Cell therapy product development

While the private sector consolidates, many public (nonprofit) cord blood banks, particularly in the U.S., are struggling financially. These banks spend between $1 million and $6 million annually on processing, testing, storage, and licensing technologies. Revenue from cord blood sales is relatively low, often supplemented by government subsidies, donations, and grants.

The umbilical cord blood and tissue market is composed of several segments:

1. Storage (Cryopreservation) Market: This segment generates significant revenue from long-term storage contracts. Major investment firms have recently entered this market by acquiring stakes in cord blood banking companies.
2. Transplantation Medicine: There is a robust market for using cord blood in treating diseases such as leukemia and sickle cell disease. Over 40,000 UCB transplants have been performed, and the U.S. FDA has approved over 80 medical conditions for treatment using hematopoietic stem cells (HSCs) from cord blood.
3. Regenerative Medicine: Research into cord blood and tissue for regenerative medicine is growing. Studies from the mid-2000s have shown the potential of cord blood for treating neurological disorders. For instance, clinical trials have demonstrated the safety and effectiveness of minimally manipulated cord blood in treating conditions like cerebral palsy and autism. RheinCell Therapeutics, now owned by Catalent, has achieved GMP certification for manufacturing cord blood-derived iPSCs for cell therapy.
4. Research Supply Products: There is a growing market for research products derived from cord blood and tissue, including cells, tissues, reagents, and kits. Leading market players like Lonza, STEMCELL Technologies, and AllCells are major contributors to this sector.

This report provides insights into the following:

The number of cord blood units stored globally, in both public and private banks.
The number of hematopoietic stem cell transplants performed using cord blood cells.
Utilization of cord blood in regenerative medicine clinical trials.
Trends in cord blood use for HSCTs since 2005.
Emerging technologies impacting the financial stability of public cord blood banks.
Future opportunities for companion products derived from cord blood.
The evolving landscape of cord blood banking.
Expansion and extension of services by cord blood banks.
Economic models and cost analyses for public and private cord blood banks.
Pricing for processing and storage in private banks.
Comparative analysis of cord blood processing technologies and their merits.
Number and types of clinical trials and patents related to cord blood and tissue.
Transplantation data from different cord blood registries.

The report also answers key questions such as:

Strategies for improving the financial stability of public cord blood banks.
Companion products developed from cord blood.
Costs and revenues associated with processing and storing cord blood.
Comparative pricing and revenue for cord blood units in different regions.
Accreditation systems and processing technologies for cord blood banks.
Utilization rates and research focus areas for cord blood and tissue-derived cells.

This comprehensive report provides a detailed analysis of the cord blood and tissue banking market, including historical data and future projections through 2032. It covers storage, processing technologies, market leaders, and recent M&A activity, market size metrics, forecasts, and so much more.

1. REPORT OVERVIEW

1.1. Statement of the Report
1.2. Executive Summary
1.3. Introduction

2. CORD BLOOD & CORD BLOOD BANKS: AN OVERVIEW

2.1. Composition of a Cord Blood Sample
2.2. Cord Blood Banks
- 2.2.1. Public Cord Blood Banks
  - 2.2.1.1. WMDA Registry on Global Cord Blood Units
  - 2.2.1.2. Public Cord Blood Banks in the U.S.
  - 2.2.1.3. Public Cord Blood Banks in Major European Countries
  - 2.2.1.4. Economic Model of Public Cord Blood Banks
  - 2.2.1.5. Cost Analysis for Public Cord Blood Banks
  - 2.2.1.6. Relationship between Cost and Release Rates
- 2.2.2. Private Cord Blood Banks
  - 2.2.2.1. Private Cord Blood Banks in the U.S.
  - 2.2.2.2. World's Top Ten Private Cord Blood Banks by Size of Inventory
  - 2.2.2.3. Processing and Storage Charges in Private Cord Blood Banks, U.S.
  - 2.2.2.4. Processing & Storage Charges in Private Banks in Europe
  - 2.2.2.5. Processing and Storage Fee Charged by LifeCell (India)
  - 2.2.2.6. Processing & Storage Fees Charged by Global Cord Blood Corp. (China)
  - 2.2.2.7. Cost Analysis for Private Cord Blood Banks
  - 2.2.2.8. Revenue Generation by Private Cord Blood Banks
  - 2.2.2.9. Status and Noteworthy Features of Some U.S. Private Cord Blood Banks
  - 2.2.2.10. Public vs. Private Cord Blood Banks
- 2.2.3. Hybrid Cord Blood Banks
  - 2.2.3.1. Proportion of Public, Private and Hybrid Cord Blood Banks
- 2.2.4. Community Cord Blood Banks
2.3. Percent Share of Parents Storing Cord Blood by Country (Top 10)
2.4. The Unique Benefits of Cord Blood Transplant

3. CORD BLOOD BANK ACCREDITATIONS

3.1. Association for the Advancement Blood and Biotherapies (AABB)
- 3.1.1. AABB Accreditation Phases and Expectations
3.2. Foundation for the Accreditation of Cellular Therapy (FACT)
- 3.2.1. FACT Standards
- 3.2.3. FACT Accreditation Process
3.3. FDA-Registered Cord Blood Banks
3.4. FDA Biologics Application for Cord Blood
3.5. Investigation New Drug (IND) for Cord Blood
3.6. Human Tissue Authority (HTA)
3.7. Therapeutic Goods Act (TGA)

4. PATENT LANDSCAPE OF CORD BLOOD, CORD TISSUE & PLACENTA

4.1. Patents on Umbilical Cord Blood Stem Cells
- 4.1.1. Legal Status of Cord Blood Stem Cell Patents
- 4.1.2. Umbilical Cord Blood Stem Cell Patent Applications by Year
- 4.1.3. Cord Blood Stem Cell Patent Applications by Jurisdiction
- 4.1.4. Umbilical Cord Blood Stem Cell Patent Applicants
- 4.1.5. Umbilical Cord Blood Stem Cell Inventors
- 4.1.6. Owners of Umbilical Cord Blood Stem Cell Patents
4.2. Patents of Umbilical Cord Tissue
- 4.2.1. Legal Status of Cord Tissue Patents
- 4.2.2. Umbilical Cord Tissue Patent Applications by Year
- 4.2.3. Umbilical Cord Tissue Patent Applications by Jurisdiction
- 4.2.4. Umbilical Cord Tissue Patent Applicants
- 4.2.5. Inventors of Umbilical Cord Tissue Patents
- 4.2.6. Owners of Umbilical Cord Tissue Patents
4.3. Patents on Placental Tissue
- 4.3.1. Placental Tissue Patent Applicants
- 4.3.2. Placental Tissue Patent Applications by Year
- 4.3.3. Placental Tissue Patents by Jurisdiction
- 4.3.4. Inventors of Placental Tissue Patents
- 4.3.5. Owners of Placental Tissue Patents
- 4.3.6. Legal Status of Placental Tissue Patents
4.4. Patents on Cord Blood Expansion
- 4.4.1. Number of Cord Blood Expansion Patent Applications by Year
- 4.4.2. Cord Blood Expansion Patent Applications by Jurisdiction
- 4.4.3. Legal Status of Cord Blood Expansion Patents
- 4.4.4. Inventors of Cord Blood Expansion Patents
- 4.4.5. Owners of Cord Blood Expansion Patents

5. UMBILICAL CORD BLOOD RESEARCH PUBLICATIONS

5.1. Number of Papers Published on Umbilical Cord Blood (UCB)
5.2. Number of Papers Published in PubMed.gov on Umbilical Cord Tissue
5.3. Number of Papers Published on Placental Tissue
5.4. Published Papers on Cord Blood Expansion Methods

6. CLINICAL TRIAL DATA

6.1. Clinical Trials Using Umbilical Cord Blood Units (CBUs)
- 6.1.1. Number of Umbilical Cord Blood Clinical Trials by Study Type
- 6.1.2. Number of Cord Blood Clinical Trials by Phase of Study
- 6.1.3. Number of Cord Blood Clinical Trials by Funder Type
- 6.1.4. Diseases Addressed by Ongoing Cord Blood Clinical Trials
- 6.1.5. Companies Participating in Cord Blood Clinical Trials, April 18, 2025
6.2. Clinical Trials using Umbilical Cord Tissue
- 6.2.1. Umbilical Cord Tissue Clinical Trials by Phase of Study
- 6.2.2. Umbilical Cord Tissue Clinical Trials by Funder Type
- 6.2.3. Umbilical Cord Tissue Clinical Trials Sponsored by Companies
6.3. Placental Tissue Stem Cells in Clinical Trials
- 6.3.1. Placental Tissue Stem Cells in Clinical Trials by Phase of Study
6.4. Clinical Trials using Expanded Cord Blood
- 6.4.1. Major Participants in Expanded Cord Blood Clinical Trials

7. CORD BLOOD PROCESSING TECHNOLOGIES

7.1. The Process of Separation of Cord Blood Stem Cells
- 7.1.1. Plasma Depletion (MaxCell Process)
- 7.1.2. Density Gradient
- 7.1.3. Hetastarch (HES)
- 7.1.4. PrepaCyte-CB
- 7.1.5. SEPAX
- 7.1.6. AutoXpress (AXP)
- 7.1.7. TotiCyte
- 7.1.8. MacoPress Smart
7.2. Performance Comparison of Cord Blood Processing Technologies
7.3. Days to Neutrophil Engraftment by Processing Technology
7.4. Anticoagulants used in Cord Blood Processing
7.5. Cryopreservation of Umbilical Cord Blood
7.6. Bioprocessing of Umbilical Cord Tissue
7.7. Cord Blood Expansion Technologies
- 7.7.1. Umbilical Cord Blood Expansion Strategies
  - 7.7.1.1. Aryl Hydrocarbon Antagonists
  - 7.7.1.2. Pyrimidoindole Derivatives
  - 7.7.1.3. Nicotinamide
  - 7.7.1.4. Notch Ligands
  - 7.7.1.5. Copper Chelator
  - 7.7.1.6. Valproic acid

8. CORD BLOOD UNITS AVAILABLE WORLDWIDE: AN OVERVIEW

8.1. Number of Cord Blood Donors & CBUs Available Worldwide
8.2. CBUs Available by Geography
8.3. Cord Blood Units (CBUs) Registered in U.S. Registries
- 8.3.1. Cord Blood Units (CBUs) in the U.S. by Race and Ethnicity as of 2024
8.4. CBUs Available in Europe
8.5. CBUs Available in Asia/Pacific
8.6. HLA Typing of Unrelated Cord Blood Donors and CBUs Worldwide
- 8.6.1. Unrelated BM, PB and CB HSCs Shipped Worldwide
- 8.6.2. Global Exchange of Cord Blood Units (CBUs)
8.7. WMDA's Search & Match Service
- 8.7.1. Number of Searches made in WMDA Registry for CBUs by Year
- 8.7.2. Yield of Search Results from WMDA Registry, 2017-2023

9. INDICATIONS FOR UBC TRANSPLANTATION

9.1. Advantages of Cord Blood Stem Cells
- 9.1.1. Hematopoietic Properties of Cord Blood Stem Cells
- 9.1.2. Immune Properties of Cord Blood Stem Cells
- 9.1.3. Impact of HLA Mismatch in UCB Transplant Recipients
9.2. Malignant Indications Addressable by UCB Transplantation
9.3. Non-Malignant Indications for CBU Transplantation
9.4. Application of UCB in Regenerative Medicine

10. CORD BLOOD: A TRANSPLANT MEDICINE

10.1. Worldwide PB, BM & CB Transplants Compared
10.2. Cord Blood Stem Cells Transplantation by Geography
- 10.2.1. CBU Transplantations in Asia
- 10.2.2. UCB Transplants in North America
- 10.2.3. UCB Transplants in Europe
- 10.2.4. UCB Transplants in Oceania
- 10.2.5. CBU Transplants in South America
10.3. Cost of UCB Transplantation
- 10.3.1. Complications through 1-Year Post HSCT

11. CORD BLOOD STEM CELLS IN REGENERATIVE MEDICINE

11.1. Autism
11.2. Cerebral palsy
11.3. Alzheimer's Disease
11.4. Diabetes
11.5. Heart Diseases
11.6. Multiple Sclerosis
11.7. Stroke

12. MARKET ANALYSIS

12.1. Umbilical Cord Blood Banking Services Market
- 12.1.1. Umbilical Cord Blood (UCB) Banking Market Share by Geography, 2024
- 12.1.2. Public vs. Private Cord Blood Banking Service Market
- 12.1.3. Global Market Share for Cord Blood & Cord Tissue Banking Services
- 12.1.4. Market Share of CB for Transplantation & Regenerative Medicine
- 12.1.5. Percent Share of Cord Blood & Cord Tissue Market by Indication
12.2. Global Market for Umbilical Cord Tissue Banking Service
12.3. Historical Revenue Analysis of the Cord Blood Industry
12.4. Geographical Revenue Variations in Cord Blood Banking
12.5. Innovations Impacting Cord Blood Banking Revenue
12.6. Growth Drivers for the Cord Blood Industry

13. PROFILES OF SELECT CORD BLOOD BANKS & RELATED ORGANIZATIONS

13.1. AllCells
- 13.1.1. Research Use Only (RUO) Products
  - 13.1.1.1. Mobilized Leukopak
  - 13.1.1.2. Leukopak
  - 13.1.1.3. Bone Marrow
  - 13.1.1.4. Cord Blood
  - 13.1.1.5. Whole Blood
- 13.1.2. GMP Products
  - 13.1.2.1. Clinical Grade Mobilized Leukopak
  - 13.1.2.2. Clinical Grade Leukopak
  - 13.1.2.3. Clinical Grade Bone Marrow
- 13.1.3. Isolated Cell Products
  - 13.1.3.1. CD34+ HSPCs
  - 13.1.3.2. T Cells
  - 13.1.3.3. NK Cells
  - 13.1.3.4. Monocytes
  - 13.1.3.5. B Cells
  - 13.1.3.6. PBMCs (MNCs)
13.2. AlphaCord
- 13.2.1. Prices
13.3. Americord Registry, Inc.
13.4. Angiocrine Bioscience
- 13.4.1. Proprietary E-CEL Platform
13.5. Anja Health Personalized Cord Blood Banking
- 13.5.1. Anja's Mannual Processing of Cord Blood
13.6. Anthony Nolan
- 13.6.1. Products & Services
  - 13.6.1.1. Cell Isolation & Purification
  - 13.6.1.2. Cell Culture & Expansion
13.7. Baylx, Inc.
- 13.7.1. Core Technology
- 13.7.2. Product Piupeline
13.8. NMDPSM
- 13.8.1. NMDP Network
13.9. Biocell Center
13.10. BioEden
- 13.10.1. Dental Pulp Cells
- 13.10.2. Differences between Dental Pulp Cells and Cord Blood Cells
13.11. BioIntegrate, LLC
- 13.11.1. GeneXSTEM Injectables
13.12. Bloodworks Northwest
- 13.12.1. Products & Services
13.13. California Umbilical Cord Collection Program
- 13.13.1. Participating Locations
13.14. Carolinas Cord Blood Bank (CCBB)
13.15. Celaid Therapeutics
- 13.15.1. In Vitro Expansion Technology
- 13.15.2. Business Model
13.16. Celebration Stem Cell Centre (CSCC)
- 13.16.1. Products
13.17. Cell Care
13.18. Cellenkos, Inc.
- 13.18.1. Technology
- 13.18.2. Cellenkos' Pipeline
13.19. Cells4Life Group LLP
- 13.19.1. Cellsplus
- 13.19.2. TotiCyte Processing Technology
- 13.19.3. Cord Blood Releases from Cells4Life
13.20. CellSave Arabia
- 13.20.1. Cord Blood Stem Cell Banking Services
- 13.20.2. Stem Cell Banking Price
13.21. Celularity, Inc.
13.22. Center for International Blood and Marrow Transplant Research (CIBMTR)
13.23. CHOC Blood Bank
13.24. Cleveland Cord Blood Center
- 13.24.1. Research on Diabetic Retinopathy
- 13.24.2. Research on Type I Diabetes
- 13.24.3. Research on Parkinson's disease
- 13.24.4. Research on Wound Healing
13.25. ClinImmune Cell and Gene Therapy
- 13.25.1. FDA Licensed Cord Blood
- 13.25.2. Gene Therapy
- 13.25.3. Cellular Therapies
13.26. Cord Blood Bank of Arkansas (CBBA)
13.27. Cord Blood Center Group
13.28. Cord Blood Registry (CBR)
- 13.28.1. Business Experience
- 13.28.2. Licensing & Accreditation
- 13.28.3. Pricing
13.29. Cord for Life
- 13.29.1. Technology: PremierMax
13.30. CordLife Group, Ltd.
- 13.30.1. Accreditations & Certifications
- 13.30.2. Services
- 13.30.3. Cordlife Group's Network
- 13.30.4. Cordlife's Market
13.31. CordVida
13.32. Crioestaminal
- 13.32.1. Cord Blood Transplantation in Portugal
13.33. Cryo-Cell International, Inc.
- 13.33.1. Processing Technology
- 13.33.2. Recovery of Viable CFU by PrepaCyte-CB
- 13.33.3. Cryo-Cell International's Revenue Generation
- 13.33.4. Cryo-Cell International's Pricing
13.34. CryoCyte, LLC
13.35. CryoHoldco LATAM
13.36. Cryopoint
13.37. Cryoviva Biotech Pvt., Ltd.
13.38. DKMS gGMBH
- 13.38.1. Cord Blood Units
- 13.38.2. Services
- 13.38.3. DKMS' Donor Typing Profile & Active Donors
13.39. Duke University School of Medicine
- 13.39.1. Ducord (HPC Cord Blood)
13.40. European Society for Blood and Bone Marrow Transplantation (EBMT)
- 13.40.1. EBMT Transplant Activity
13.41. Ever Supreme Bio Technology, Co., Ltd.
- 13.41.1. Allogeneic UMSC01
- 13.41.2. New Research
13.42. ExCellThera
- 13.42.1. ECT-001 Cell Therapy
13.43. FamiCord Group
13.44. Fate Therapeutics, Inc.
- 13.44.1. FT1050 - Stem Cell Modulator
13.45. Future Health
- 13.45.1. Locations of Laboratories
- 13.45.2. Business Experience
- 13.45.3. Collection Kit
- 13.45.4. Transportation Container
- 13.45.5. Processing Method
- 13.45.6. Components Stored
- 13.45.7. Storage Methods
- 13.45.8. Licensing & Accreditation
- 13.45.9. Prices
- 13.45.10. Additional Services
13.46. Gamida Cell
- 13.46.1. OMIDUBICELL
13.47. GeneCell
13.48. Global Cord Blood Corporation (GCBC)
- 13.48.1. GCBC's Revenue Generation
13.49. Glycostem Therapeutics
- 13.49.1. Science and Technology
- 13.49.2. oNKord
- 13.49.3. viveNK
- 13.49.4. uNiK Production Process
13.50. Hawaii Cord Blood Bank
13.51. HealthBaby
- 13.51.1. Service Plans
- 13.51.2. 18-Year Cord Blood (HSCs) Storage Plan
- 13.51.3. 18-Year CordBasic Umbilical Cord Lining Storage Plan
- 13.51.4. CellOptima CordPlus Umbilical Cord Lining Storage
13.52. HealthBanksUSA
- 13.52.1. BioArchive Cryogenic Storage System
- 13.52.2. AXP Cord Blood Processing
13.53. HEMAFUND
13.54. Hemogenyx Pharmaceuticals
- 13.54.1. Technology
13.55. IMMUNIQUE
13.56. Insception LifeBank
- 13.56.1. Cord Blood Releases from Insception LifeBank
- 13.56.2. Cord Blood Cells Released for Regenerative Medicine from Insception
13.57. JP McCarthy Cord Stem Cell Bank
13.58. Kangstem Biotech, Co., Ltd.
- 13.58.1. GD11 Brand
- 13.58.2. Core Technology
13.59. LifebankUSA
13.60. LifeCell International Pvt. Ltd.
13.61. Life Line Stem Cell
13.62. LifeSouth Cord Blood Bank
- 13.62.1. Accreditation & Hospital Partners
13.63. Magenta Therapeutics
- 13.63.1. Magenta's Cord Blood-Based Clinical Trial
13.64. Maze Cord Blood
13.65. Medipost, Co., Ltd.
- 13.65.1. Medipost's Product & Products in Development
  - 13.65.1.1. CARTISTEM
  - 13.65.1.2. PNEUMOSTEM
  - 13.65.1.3. SMUP-IA-01
13.66. MD Anderson Cord Blood Bank
13.67. Mesoblast, Ltd.
- 13.67.1. Mesoblast's UCB-Based Clinical Trial
13.68. MiracleCord, Inc.
- 13.68.1. AXP II Automated Processing
- 13.68.2. StemCare Collection Kit
- 13.68.3. Cost of Cord Blood Banking
13.69. Mononuclear Therapeutics, Ltd.
- 13.69.1. MonoTx Cord Blood Bank
- 13.69.2. MonoTx's Pipeline
- 13.69.3. Products
  - 13.69.3.1. Human Cord Blood Mononuclear Cells (MNCs)
  - 13.69.3.2. Exosome Rich Plasma (ERP)
  - 13.69.3.3. Activated Human Cord Blood Platelet-Depleted-Plasma (aPDP)
13.70. New England Cord Blood Bank, Inc.
- 13.70.1. Cord Blood Processing
- 13.70.2. Cord Blood & Tissue Storage
13.71. New York Blood Center
- 13.71.1. Blood Products & Services
- 13.71.2. Cell Therapies
- 13.71.3. Cord Blood
13.72. OrganaBio
- 13.72.1. OrganaBio's Proprietary Supply Chains
- 13.72.2. Perenatal Tissues
13.73. PacifiCord
- 13.73.1. FDA-Approved Sterile Collection Bags
- 13.73.2. AXP Processing System
- 13.73.3. BioArchive System
13.74. Plasticell Ltd.
- 13.74.1. CombiCult Technology
- 13.74.2. Hematopoietic Stem Cell Expansion
13.75. ReeLabs Pvt. Ltd.
13.76. Restem, LLC
- 13.76.1. Clinical Trial for COVID-19
- 13.76.2. Clinical Trial for Muscular Dystrophy
- 13.76.3. Clinical Trial for Idiopathic Inflammatory Myositis (IIM)
- 13.76.4. Clinical Trial for Heart Failure
13.77. San Diego Cord Blood Bank
13.78. Saneron CCEL Therapeutics, Inc.
- 13.78.1. U-CORD-CELL Program
- 13.78.2. SERT-CELL Program
13.79. SmartCells
13.80. SSM Cardinal Glennon Children's Medical Center
- 13.80.1. ALLOCORD
13.81. Stembanc, Inc.
- 13.81.1. Popular Packages from Stembanc
13.82. Stem Cell Cryobank, Inc.
13.83. StemCyte, Inc.
- 13.83.1. Services
- 13.83.2. Add On Services
- 13.83.3. StemCyte in Clinical Trials
- 13.83.4. StemCyte's Plans & Pricing
13.84. Throne Biotechnologies, Inc.
- 13.84.1. Effects of CB-SCs in Diabetics
- 13.84.2. Effects of CB-SCs on Alopecia Areata
13.85. Transcell Biolife
- 13.85.1. ScellCare
- 13.85.2. ToothScell
13.86. Upstate Cord Blood Bank
13.87. ViaCord
- 13.87.1. ViaCord's Complete Services
- 13.87.2. Cord Blood + Tissue Banking
- 13.87.3. Newborn Digestive Health
- 13.87.4. Newborn DNA Guardian
13.88. Versity, Inc.
13.89. Vita 34 AG (Recently Merged with Famicord)
- 13.89.1. Revenue Generation by Vita 34 AG
13.90. Vitalant Clinical Services
- 13.90.1. Hospital Services
- 13.90.2. Laboratory Services
- 13.90.3. Research
13.91. World Marrow Donor Association (WMDA)
- 13.91.1. WMDA Search & Match Service
13.92. Worldwide Network for Blood & Marrow Transplantation (WBMT)

APPENDIX

APPENDIX 1: Advancements in Umbilical Cord Blood Banking
Appendix 1.1: Market Growth and Trnds
Appendix 1.2: Advances in Automation and Cryopreservation
Appendix 1.3: Advances in Isolation Methods
Appendix 1.4: Expanding Applications of CBUs
Appendix 1.5: Potential of Artificial Intelligence (AI) in UCB Banking

INDEX OF FIGURES

FIGURE 2.1: Schematic Cross-Sectional View of Umbilical Cord
FIGURE 2.2: Percent Utilization of HSCs by Type in Pediatric Patients
FIGURE 2.3: Composition of a Cord Blood Sample
FIGURE 2.4: World's Top Ten Private Cord Blood Banks by Inventory Size
FIGURE 2.5: Revenue Generation in Three Major Private Cord Blood Banks, 2017-2024
FIGURE 2.6: Proportion of Public, Private and Hybrid Cord Blood Banks
FIGURE 2.7: Percent Share of Parents Storing Cord Blood in Top Ten Countries
FIGURE 4.1: Legal Status of Umbilical Cord Blood Stem Cell Patents
FIGURE 4.2: Number of Applications for Umbilical Cord Blood Stem Cells, 2000-2024
FIGURE 4.3: Legal Status of Cord Tissue Patents
FIGURE 4.4: Umbilical Cord Tissue Patent Applications, 2000-2024
FIGURE 4.5: Placental Tissue
FIGURE 4.6: Placental Tissue Patent Applications by Year
FIGURE 4.7: Cord Blood Expansion Patent Applications by Year
FIGURE 5.1: Number of Papers on Umbilical Cord Blood in PubMed.gov, 2000-2024
FIGURE 5.2: Number of Papers Published in PubMed.gov on Cord Tissue, 2000-2024
FIGURE 5.3: Number of Published Papers on Placental Tissue, 2000-2024
FIGURE 5.4: Published Papers on Cord Blood Expansion in PubMed.gov
FIGURE 6.1: Percent Share of UCB Clinical Trials by Study Type, April 18, 2025
FIGURE 6.2: Percent Share of Cord Blood Clinical Trials by Phase of Study, April 18, 2025
FIGURE 6.3: Percent Share of Cord Blood Clinical Trials by Funder Type, April 18, 2025
FIGURE 6.4: Percent Share of Studies Addressing Various Diseases, April 18, 2025
FIGURE 6.5: Umbilical Cord Tissue Clinical Trials by Phase of Study, April 19, 2025
FIGURE 6.6: Umbilical Cord Tissue Clinical Trials, April 19, 2025
FIGURE 6.7: Placental Stem Cells in Clinical Trials by Phase of Study, April 19, 2025
FIGURE 7.1: The Buffy Coat of Cord Blood after Centrifugation
FIGURE 7.2: Cord Blood Sample Bag after Plasma Depletion
FIGURE 7.4: PrepaCyte-CB System
FIGURE 7.5: SEPAX
FIGURE 7.6: AutoXpress
FIGURE 7.7: TotiCyte Processing Steps
FIGURE 7.9: Percent Viable Stem Cells in the Processed Cord Blood by Technology
FIGURE 7.10: Days to Neutrophil Engraftment by Technology
FIGURE 7.11: Stem Cell (CD34+) and Nucleated White Cell Count with CPD and Heparin
FIGURE 7.12: A Comparative Analysis with Three Different Cryoprotectants
FIGURE 8.1: Number of CB Donors and CBUs available Worldwide, 1997-2024
FIGURE 8.2: Cord Blood Units (CBUs) Registered in the U.S. Registries by Year, 2001-2024
FIGURE 8.3: HLA Typing of Unrelated Cord Blood Donors and CBUs Worldwide
FIGURE 8.4: HSCs of BM, PB and CB Shipped Worldwide, 1997-2023
FIGURE 8.5: Global Exchange of CBUs, 2023
FIGURE 8.6: Number of Searches made in WMDA Registry for CBUs, 2017-2023
FIGURE 8.7: Yield of Search Results from WMDA Registry, 2017-2023
FIGURE 9.1: Percent Utilization of PB, BM and CB Worldwide, 1997-2023
FIGURE 10.1: Worldwide PB, BM & CB Transplants Compared
FIGURE 10.2: CBU Transplantations in Asia, 1999-2003
FIGURE 10.3: UCB Transplants in North America
FIGURE 10.4: CUB Transplants in Europe
FIGURE 10.5: UCB Transplants in Oceania
FIGURE 12.1: Global Cord Blood Banking Service Market, 2024-2032
FIGURE 12.2: Percent Share of Cord Blood Service Market by Geography, 2024
FIGURE 12.3: Public vs. Private Cord Blood Banking Service Market
FIGURE 12.4: Global Market Share for Cord Blood & Cord Tissue Banking Services, 2024
FIGURE 12.5: Market Share of CB for Transplantation & Regenerative Medicine
FIGURE 12.6: Percent Share of Cord Blood & Cord Tissue Market by Indication
FIGURE 13.1: Funders for CIBMTR in 2023
FIGURE 13.2: Sales Revenues and Gross Profits for CordLife, 2014-2023
FIGURE 13.3: Cryo-Cell International's Revenue Generation, 2017-2023
FIGURE 13.4: GCBC's Revenue Generation, 2015-2022
FIGURE 13.5: Revenue Generation by Vita 34 AG, 2014-2021
FIGURE App.1.1: Proportion of Clinical Conditions Investigated using UCB-MSCs

INDEX OF TABLES

TABLE 2.1: General Features of Public Cord Blood Banks
TABLE 2.2: Number of CBUs in WMDA Registry
TABLE 2.3: Public Cord Blood Banks in the U.S.
TABLE 2.4: Public Cord Blood Banks in European Countries
TABLE 2.5: International Prices of Cord Blood Unit (CBU)
TABLE 2.6: Prices of CBUs in NMDP Banks in the U.S.
TABLE 2.7: General Features of Private Cord Blood Banks
TABLE 2.8: Leading Private Cord Blood Banks in the U.S.
TABLE 2.9: World's Top Ten Private Cord Blood Banks by Inventory Size
TABLE 2.10: Processing and Storage Charges in CBR (U.S.)
TABLE 2.11: Processing and Storage Fee Charged by Vita34 (Europe)
TABLE 2.12: Processing and Storage Fees Charged by LifeCell (India)
TABLE 2.13: Processing & Storage Fees Charged by Global Cord Blood Corp. (China)
TABLE 2.14: Revenue Generation by Three Major Private Cord Blood Banks, 2017-2024
TABLE 2.15: Examples of Hybrid Cord Blood Banks
TABLE 2.16: Percent Share of Parents Storing Cord Blood in Top Ten Countries
TABLE 3.1: AABB Accredited Cord Blood Banks
TABLE 3.2: Select FACT-Accredited Cord Blood Banks
TABLE 4.1: Legal Status of Umbilical Cord Stem Cell Patents
TABLE 4.2: Umbilical Cord Blood Stem Cell Patent Applications by Year
TABLE 4.3: Umbilical Cord Blood Patent Applications by Jurisdiction
TABLE 4.4: Applicants of Umbilical Cord Patents
TABLE 4.5: Umbilical Cord Blood Stem Cell Patent Inventors
TABLE 4.6: Owners of Umbilical Cord Blood Stem Cell Patents
TABLE 4.7: Legal Status of Cord Tissue Patents
TABLE 4.8: Number of Umbilical Cord Tissue Patent Applications, 2000-2024
TABLE 4.9: Umbilical Cord Tissue Patent Applications by Jurisdiction
TABLE 4.10: Umbilical Cord Tissue Patent Applicants
TABLE 4.11: Umbilical Cord Tissue Patent Inventors
TABLE 4.12: Owners of Umbilical Cord Tissue Patents
TABLE 4.13: Placental Tissue Patent Applicants
TABLE 4.14: Placental Tissue Patent Applications by Year
TABLE 4.15: Placental Tissue Patent Jurisdictions
TABLE 4.16: Inventors of Placental Tissue Patents
TABLE 4.17: Owners of Placental Tissue Patents
TABLE 4.18: Legal Status of Placental Tissue Patents
TABLE 4.19: Cord Blood Expansion Patent Applications by Year
TABLE 4.20: Cord Blood Expansion Patent Applications by Jurisdiction
TABLE 4.21: Legal Status of Cord Blood Expansion Patents
TABLE 4.22: Inventors of Cord Blood Expansion Patents
TABLE 4.23: Owners of the Cord Blood Expansion Patents
TABLE 6.1: Total Number of Clinical Trials (CBU, CT, PT and Expanded CBU), Apr. 2025
TABLE 6.2: Number of Umbilical Cord Blood Clinical Trials by Study Type, April 18, 2025
TABLE 6.3: Number of Cord Blood Clinical Trials by Phase of Study, April 18, 2025
TABLE 6.4: Number of Cord Blood Clinical Trials by Funder Type, April 18, 2025
TABLE 6.5: Select Companies Sponsoring Cord Blood Clinical Trials
TABLE 6.6: Umbilical Cord Tissue Clinical Trials by Phase of Study, April 19, 2025
TABLE 6.7: Umbilical Cord Tissue Clinical Trials by Funder Type, April 19, 2025
TABLE 6.8: Select Companies Sponsoring Cord Tissue Clinical Trials, April 19, 2025
TABLE 6.9: Placental Tissue Stem Cells in Clinical Trials by Phase of Study, April 19, 2025
TABLE 6.10: Major Clinical Trials Using Expanded Umbilical Cord Blood Cells
TABLE 7.1: Umbilical Cord Blood Expansion Strategies
TABLE 8.1: Umbilical Cord Blood Units Registered with WMDA, April 22, 2025
TABLE 8.2: Number of CB Donors and CBUs available Worldwide, 1997-2024
TABLE 8.3: Number of Cord Blood Donors and CBUs available by Geography, 2023
TABLE 8.4: Available CBUs in the U.S. by Race & Ethnicity, September 30, 2024
TABLE 8.5: CBUs Available in Europe as of April 23, 2025
TABLE 8.6: CBUs Available in Asia/Pacific as of April 23, 2025
TABLE 8.7: HSCs of BM, PB and CB Shipped Worldwide, 1997-2023
TABLE 8.8: Number of Searches made in WMDA Registry for CBUs, 2017-2023
TABLE 8.9: Yield of Search Results from WMDA Registry, 2017-2023
TABLE 9.1: Malignant Indications Addressed by UCB Transplantation
TABLE 9.2: Non-Malignant Indications for CUB Transplantation
TABLE 9.3: Diseases Targeted by Cord Blood Cells as Regenerative Medicines
TABLE 10.1: Worldwide PB, BM & CB Transplants Compared
TABLE 10.2: CBU Transplantations by Geography, 1999-2023
TABLE 10.3: Comparison of Median Cost during Admit for CB, PB and BM HSCTs
TABLE 10.4: Complications through 1-Year Post HSCT
TABLE 11.1: UCB & UCBT in Clinical Trials on Autism
TABLE 11.2: A Sample List of Clinical Trials for Cerebral Palsy using CBUs
TABLE 11.3: A Sample List of Clinical Studies for Alzheimer's Disease using CBUs
TABLE 11.4: A Sample List of Clinical Studies for Diabetes using CBUs
TABLE 11.5: A Small List of Clinical Studies for Heart Diseases using CBUs
TABLE 11.6: A Short List of Clinical Studies for Multiple Sclerosis using CBUs
TABLE 12.1: Global Cord Blood Banking Service Market, 2024-2032
TABLE 12.2: Global Market for Cord Tissue Banking Service, 2024-2032
TABLE 13.1: Angiocrine's R&D Pipeline
TABLE 13.2: Baylx's hUC-MSC-Derived Product Pipeline
TABLE 13.3: NMDP Network of Cord Blood Banks
TABLE 13.4: Cell Care's Pricing for Cord Blood Processing and Storage
TABLE 13.5: Cellenkos' Product Pipeline
TABLE 13.6: Cord Blood Releases from Cells4Life
TABLE 13.7: Celularity's Active Clinical Pipeline
TABLE 13.8: Recovery of Viable CFU by PrepaCyte-CB
TABLE 13.9: Cryo-Cell International's Revenue Generation, 2017-2023
TABLE 13.10: Cryo-Cell International's Pricing
TABLE 13.11: CryoCyte's Option Plans & Pricing
TABLE 13.12: DKMS' Donor Typing Profile & Active Donors
TABLE 13.13: EBMT Transplant Activity, 2023
TABLE 13.14: Cord Blood Banking Cost in GeneCell
TABLE 13.15: GCBC's Revenue Generation, 2015-2022
TABLE 13.16: Glycostem's Product Pipeline
TABLE 13.17: Insception LifeBank's Pricing
TABLE 13.18: Cord Blood Releases from Insception LifeBank for Transplantation
TABLE 13.19: Cord Blood Cells Released for Regenerative Medicine from Insception
TABLE 13.20: Kangstem's Sponsor Initiated Clinical Trials
TABLE 13.21: LifeCell International's Pricing
TABLE 13.22: Maze Cord Blood: Banking Cost
TABLE 13.23: MiracleCord's Cord Blood Banking Cost
TABLE 13.24: MonoTx's Product Pipeline